Membrane Protein Antibody Discovery, MPSA AB5000

De-Risk the off-target interactions of your antibody drug for IND application.

Antibody Discovery Services

MPSA-AB5000 Introduction

The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. The lack of suitable methods to identify the targets of functional antibodies and ligands result in drug safety accidents and the abandonment of previous studies. KYinno’s Membrane Proteins Screening Array (MPSA-AB5000) is an excellent solution for antibody specificity screening which enable early off-target screening and can de-risk the antibody drug development program.

Full Coverage of Human Membrane Protein Library

The MPSA-AB5000 makes use of more than 5000 unique human membrane protein, including receptors, transporters, enzymes, miscellaneous, and others.
Natively expressed in live cells ensuring native protein conformation.

High Sensitivity Reporter System Detection

Wash-free strategy reduces false negatives.
Signal amplification makes large discrimination.
High throughput microplate system guarantees best stability and creditability.

Compatibility with Different Types of Biologic Therapeutics:

MPSA-AB5000 is compatible with monoclonal antibodies, bispecific antibodies, ADC, orphan protein and antibody, as well as CAR-T cell therapies.

Successfully Screened Off-target Molecules

Ultrashort turnaround for data report
Competitively priced

MPSA-AB5000 is rapid, simple and highly sensitive by measuring binding via reporter cell line and can determine specificity and preclinical safety of biotherapeutics conveniently.

All Antibody Discovery Services

Hybridoma Services

Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.

Single B Cell Sequencing

Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.

BiSpecific Antibodies

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.

Nanobody

Taking advantage of camelid-derived nanobodies, we present a distinct antibody structure providing exceptional therapeutic versatility. This innovation leads to innovative approaches to treatments and diagnostics and broadens the modern medical solutions.

In silico developability assessment

In silico developability assessment, transforming biomedicine by providing groundbreaking approaches to predicting antibody developability. Leveraging advanced computational insights, streamline research processes, enhance therapeutic product robustness, and accelerate innovative drug discovery.

Humanization and Affinity Maturation

With our profound expertise, we optimize antibodies for human compatibility, boosting therapeutic outcomes. Reducing adverse reactions, we lay the groundwork for innovative, patient-focused personalized medicine, customized for each individual.

Druggability and Immunogenicity Assessment

Our comprehensive assessment of drug potential and immune responses guarantees therapeutic safety and efficacy. This rigorous process is vital in bridging the transition from lab research to successful clinical stage implementation.

Membrane Protein Antibody Discovery, MPS AB5000

Using antibodies with high specificity, we guarantee precise binding targets for CAR-T cells and biologics. This meticulous approach is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.

GPCR Antibody Screening Expertise

Targeting G-protein coupled receptors, we access an expansive therapeutic domain. Concentrating on these essential proteins, we not only enhance drug efficacy but also pioneer breakthroughs, broadening horizons in modern drug development.

Heavy-chain only gene-edited mice, KY-HC-mouse

Nanobodies, featuring high affinity and stability, revolutionize therapeutic approaches. Their unique properties make them invaluable, especially in the areas of targeted drug delivery, advanced diagnostics, and innovative disease intervention strategies.

Antibody Production

KYINNO sets the standard, prioritizing high-quality antibody production. We emphasize unmatched consistency, purity, and reliability, setting industry guidelines, fostering trust, and accelerating groundbreaking drug discovery and innovative research endeavors.

Common Light Chain Antibody Mice, KY-CLC-mouse

Bispecific antibodies from KY-CLC bind two distinct antigens, offering advanced therapeutic avenues, enhancing drug delivery, and increasing the potential for successful patient outcomes.

AI Drug Discovery

Nanobodies, known for their small molecular weight, high affinity, stability, permeability, and cost-effectiveness, have demonstrated tremendous potential in disease …